{"prompt": "['LCCC XXXX', 'CONFIDENTIAL', 'PI: Zev Nakamura', 'UNIVERSITY OF NORTH CAROLINA', 'April 2017', '2.2.4 To investigate the effects of high dose IV thiamine on long-term health-', 'related quality of life (HRQOL), functional status, depression, post-traumatic', 'stress symptoms, and cognitive functioning in patients who undergo HSCT.', '3.0', 'Criteria for Evaluation / Study Endpoints', '3.1', 'Primary Endpoint', 'Delirium incidence will be defined as: DRS > 12. Delirium rating scales will be', 'performed at baseline (prior to transplant) and then three times weekly from day', 'after transplant to 30 days after transplant or discharge, whichever comes first.', '3.2', 'Secondary Enppoints', '3.2.1 Delirium duration will be measured in days and delirium severity will be', 'defined as the highest DRS score recorded. If delirium occurs, frequency of', 'assessment will increase to daily, Monday through Friday, as scheduling permits,', 'until delirium resolves.', '3.2.2 We will examine the relationship between thiamine levels at the end of the', 'seven day intervention period and the development of delirium at any point during', 'the post-transplant hospitalization.', '3.2.3 Scores on FACT-BMT, PROMIS-D, PTSS-14, ECOG-PS, and MOCA', 'will be measured at one, three, and six months after transplant.', '4.0', 'PATIENT ELIGIBILITY', 'In order to participate in this study a subject must meet ALL of the eligibility', 'criteria outlined below.', '4.1', 'Inclusion Criteria', 'Eligible subjects must meet all of the following criteria to be enrolled in the study:', '4.1.1 Admission or planned admission to the UNC Hospital Bone Marrow', 'Transplant Unit for allogeneic stem cell transplant.', '4.1.2', 'At least 18 years of age.', '4.1.3', 'Able to speak English.', '4.1.4', 'Able to provide informed consent.', '4.2', 'Exclusion Criteria', 'Eligible subjects must not have any of the following to be enrolled in the study:', '4.2.1 A history of adverse reaction to IV thiamine', '4.2.2 Pregnancy, confirmed by a negative pregnancy test within 30 days of', 'study enrollment', '8']['LCCC XXXX', 'CONFIDENTIAL', 'PI: Zev Nakamura', 'UNIVERSITY OF NORTH CAROLINA', 'April 2017', '5.0', 'TREATMENT PLAN', '5.1', 'Schema', 'Figure 1: Randomized controlled trial evaluating the efficacy of high dose', 'intravenous thiamine for prevention of delirium in allogeneic hematopoietic stem', 'cell transplantation.', 'HDIVa', 'x 7 Days', '11', '11', 'Recruitment', 'Delirium Screening', '+', 'Informed Consent', 'Serial Measurement of', 'Baseline Measuresb,c', 'Thiamine Levelsd', 'Randomization', 'Long-term Measuresb', 'a. High dose IV thiamine in intervention group only (N=30)', 'b. MOCA, FACT-BMT, PROMIS-D, PTSS-14, ECOG-PS', 'C. DRS', 'd. Thiamine levels weekly', '5.2', 'Treatment Dosage and Administration', 'Subjects in the intervention group will receive thiamine 200 mg IV tid for seven', 'days beginning on the day after of transplant. Subjects in the control group will', 'receive 100 mL (equivalent volume to intervention) normal saline IV tid for seven', 'days beginning on the day after transplant. All investigators will be blinded to', 'which patients are assigned to which arm of the study. Only the Investigational', 'Drug Service (IDS) will be aware of which patients will be assigned to which', 'arms. At any time, the PI, primary medical providers, or other emergency', \"personnel may request unblinding of a subject's randomized treatment from IDS.\", 'If there is an adverse reaction, subjects will be treated symptomatically and', 'consideration will be given to stopping the medication, as outlined in Section 5.3.', 'REGIMEN DESCRIPTION', 'Group', 'Agent', 'Dose', 'Route', 'Schedule', 'Intervention', 'Thiamine', '200 mg Thiamine', 'IV over 30', 'Post-transplant', 'HCL solution in 100', 'minutes (50', 'Days 1 - 7', 'mL infusion bag of', 'ml/hr)', 'three times daily', '0.9% Sodium', 'Chloride', '9']\n\n###\n\n", "completion": "END"}